Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How many times do I have to tell you it is not 250 million shares! It was 39 plus millions shares worth $250 million. Geezewheez!!!!
I think you’re right, plus the hold market was down and VXRT investors mostly traded by emotion. We will get back on green tomorrow, IMO. Good luck!
I wouldn’t want to take their vaccines. No thanks!
I bought more at $7.14 today. I think it will go up from here. Good luck.
The entire market is down.
Yes it’s down. Mostly manipulating by shorts, IMO. All news are good today. Not down as much as you wanted it to be? Good luck to your position, don’t get caught chasing when VXRT runs hard. JUST SAYING...
They have no case. It’s all BS from the start. The hungry lawyers keep on phishing.
By the way looks like we will stay green today. Feel sorry for the sorry whiners!
The price action today doesn’t matter. I was expecting the good results from the hamster data and it’s true enough better than I expected.
The dip this morning was likely caused by shorts trying to capitalize on the share offering thinking they could drive it down more. They didn’t expect the data was going to good and the PR this morning. Some on here said they were going sell this morning, but they are still here saying CHIT!
“Spoiler alert: there will be no news until the conference call PR.”
Until then the whining will continue. That’s a safe bet!
No need to reply to a panic prone. Thanks for your post!
Good post from on yahoo poster. Please read!
“Extremely valuable and that brings us one big step closer to massive OWS funding.
I am working for an European Risk assessment body (sorry, can't say which one, but it is not EMA) and I have assessed several hundred animal studies (mostly toxicity, infection and mechanistic studies) in the last 25 years. In addition I have also 4 years experience of molecular virology (I did my doctor in veterinary medicine) and biotechnology that included also a few animal experiments done by myself. In the early 2000s I have also assessed safety and efficacy of vaccines for an EU Member States and the European Medicine Agency (=EMA) (not working there anymore). What I can say:
Body weight is the most sensitive generic parameter for all kind of toxicity including also pathogenicity of viruses and lung toxicity. If the vaccinated masters did not lose weight like the control did (minus 8 %) - that is a very, very clear evidence that these hamsters had a protective immune response from the oral vaccination!
Regarding the mentioned relative lung organ weight: These hamsters were young and growing and gaining weight. Those hamsters not vaccinated had higher lung weight relative to body weight (called “relative lung organ weight”). This is certainly result first of the reduced body weight gain of the not vaccinated hamsters. In addition it could be partly also due an increased lung organ weight as a result of the infection there (could be seen histologically) and the subsequent inflammation (lots of cells of fluid entering the lung). Such finding on the body and lung weight - is a very very strong indication that the oral anti-covid vaccine worked extremely in hamster, for me that is basically evidence. These results on body weight and lung weight can only be explained by one reason: the vaccinated hamsters got a strong protective immune response after the vaxart vaccine ! I have no doubts that the full results will show a clear and strong immune response in the vaccinated animals and a lung inflammation of the not-vaccinated hamsters. No other possibilities here.
If the NHP show the same results – or the ongoing phase 1, then no other way than that Vaxart will get massive funding (0.5 – 1 Bio USD) from the OWS, even more likely with any further halt of the ongoing phase III trials of the injectable vaccines.
More on the hamsters: those receiving one oral dose had partial protection, those vaccinated twice were fully protected. That is inline with common knowledge and practice: twice vaccination is always better than only one. Some individuals are already sufficiently protected by one vaccination, but in general terms 2 vaccinations is always better and thus desirable. Also the other vaccines supported by OWS require 2 administrations although there maybe 1 or 2 which claim that one injection is sufficient (I doubt that 1 is as good as 2 - for any.”
Very good news. Read my post below!
NEWS NEWS NEWS!!!
Say what?
Yes, tell that to the fool that said this is going down to $2-4... lol lol. He has no idea and didn’t know how to read the news.
Do you even know what you’re talking about? They offer the shares at $7.05, how in the world you think it’s going down to $2-4?
And it’s $250 millions / $7.05 = 35,460,992 shares NOT 250,000,000 shares.
It’s a simple math!!!
“From what I read this is a $250 mill option to dilute whenever they want. It's not doubling shares to 250 mill shares. Ex: If stock goes to $10 then they can sell 25 mill shares to get to $250 mill. If stock goes to $25/share then they could sell 10mill shares. It's not the dilution people are thinking. From what I read they aren't immediately diluting. They just want the option to up to $250 mill. This may be good news long term to finance other products based on their patented VAAST oral platform. It may also be the best time to file to do this. Would you rather them announce this right before they know stock price is going to rocket? Or announce this and drive down the price momentum afterward?”
- Yahoo poster.
It’s $250 million worth of shares, NOT 250 million SHARES. Get your facts straight!!!
Which guys?
Yup. News is coming!
VERY GOOD FINANCIAL REPORT!!!
BRYAN, Texas, Oct. 13, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its financial results for the fiscal year ended June 30, 2020, which included record revenues of over $1.1 million in the fiscal fourth quarter.”
—-////————
“As of June 30, 2020, iBio had cash of approximately $55.1 million, compared with approximately $4.4 million as of June 30, 2019. Subsequent to fiscal year end, the Company completed additional ATM offerings, resulting in it having approximate cash and cash equivalents of $83.1 million on September 30, 2020.”
“Wow, BIG BUYS of 209,900, 200,000, 36,501, 69,779 and 36,501 shares, respectively....WOW WOW WOW!!!!”
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
October 13, 2020 at 8:00 AM EDT
Yes. It’s so awesome. $VXRT
I will. Hey thanks king! No whining needed!
Come back and let me know when Nasrat officially PR the trial related to this!
Elite didn’t even started trial yet. How’s that good news?
Maybe ...Maybe Friday!
After the popcorns are done, the whining continues. Same old story.
iBio Regains Compliance with NYSE American Continued Listing Standards
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that on October 1, 2020, the Company received written notice from the NYSE American LLC (“NYSEA” or the “Exchange”) stating that the Company had regained compliance with all of the Exchange’s continued listing standards set forth in Part 10 of the NYSEA Company Guide (“Company Guide”).
By meeting the requirements of the $50 million market capitalization exemption in Section 1003(a) of the Company Guide, iBio has resolved its continued listing deficiency with respect to NYSEA’s letters dated October 16, 2019 and December 9, 2019.
Tom Isett, iBio’s Chairman and Chief Executive Officer, stated, “We are pleased with the progress we have made since December 2019 on the execution of our new strategic plan. Our emphasis on proprietary biopharmaceutical development activities has not only allowed us to regain compliance with the Exchange’s listing standards, but it has also delivered new value drivers and improved financial strength for iBio. We remain focused upon building a sustainable, growth-oriented, biotech and pharma services organization that makes meaningful contributions towards addressing some of the world’s most pressing unmet medical needs. Specifically, we plan to continue to leverage the advantages afforded by our FastPharming® System and our other proprietary technologies to develop biological medicines in the area of pulmonology, including respiratory diseases like COVID-19 and fibrotic diseases of the lung, amongst others."
Thank you for your post N2K. Much appreciated. Please keep them coming!
Nice!!!!
The premarket has little effect on the opening bell. I’m not surprised.
666...LOL
Yes let’s have it open @ $3 shall we? I can only hope.
Pre- market is currently up big. Probably good news leaked?
Thanks!
It will be big.
Let me know when you get an answer! I would like to know too.